Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73762 | 0.87 | MAPT (0.60) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL2121537 | 0.87 | MAPT (0.60) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL6374257 | 0.83 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL1556456 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL7369922 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL7369923 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL12541972 | 0.79 | APAF1 (0.46) | FOLH1NAALAD2APAF1 | |
| SCHEMBL28824310 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL6010360 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTMEN1LMNAKMT2A | |
| SCHEMBL28205062 | 0.79 | ALDH1A1 (0.48) | ALDH1A1MAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045532-B2 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6632830-B1 | Blood pressure related disease or disorder, cell proliferation disorder, kidney disorder, kinetensin associated disorder, inflammation associated disorder, or an allergic disorder | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | ALDH1A1 1305/4885MAPT 2548/4885MEN1 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.